A recent study from the Department of Preventive Dentistry, Peking University School and Hospital of Stomatology, Beijing 100081, China; and Department of Periodontics, School of Dental Medicine, Philadelphia shows that “FOXO1 differentially regulates both normal and diabetic wound healing.” This study was published in the 27 April 2015 issue of Journal of Cell Biology (JCB) by Prof Dana T. Graves & Chenying Zhang, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Accelerated healing therapy for Diabetic patients: E2 (an estrogen derivative) enhances wound healing in diabetic patients via down regulation of its target gene.
Significance:
This study suggests a small molecule-based wound healing therapy for diabetic patients. E2 (an estrogen derivative), by decreasing the expression of its target gene, it may: (1) increase TGF-β1 expression and its down stream target genes; (2) increase keratinocyte migration; and (3) promote wound closure. Thereby, it may accelerate wound healing. Thus, pharmacological formulations encompassing “E2 (an estrogen derivative) or its analogues” may be used to accelerate would healing.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Accelerated healing therapy for Diabetic patients: E2 (an estrogen derivative) enhances wound healing in diabetic patients via down regulation of its target gene, 28/April/2014, 14.43, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How E2 (an estrogen derivative) accelerates wound healing in diabetic patients